ViGenCell Inc. (308080.KQ) stock: key figures, P/E, revenue and dividend
Energy · Coal & Consumable Fuels · South Korea
ViGenCell Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 278.95 m KRW | 22.67 m KRW |
| Gross profit | 11.88 m KRW | 11.06 m KRW |
| Operating income | -15.33 bn KRW | -17.11 bn KRW |
| EBIT | -13.69 bn KRW | -16.00 bn KRW |
| Net income | -14.06 bn KRW | -16.32 bn KRW |
| Diluted EPS – continuing operations | -729.64 KRW | -796.24 KRW |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
More stocks
- Elite Express Holding Inc. (ETS)
- AmpliTech Group, Inc. (AMPG)
- RAONTECH Inc. (418420.KQ)
- GlycoNex (4168.TWO)
- LTMH Public Company Limited (LTMH.BK)
- Pinetree Capital Ltd (PNP.TO)
- Sung Woo Co.,Ltd (458650.KQ)
- Sajodongaone Co Ltd (008040.KS)
- NFC Corporation (265740.KQ)
- Dong A Eltek Co. Ltd (088130.KQ)
- MHP Hotel AG (CDZ0.DE)
- OPPSTAR (0275.KL)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.